Medical technology group AOTI INC (AIM: AOTI) on Monday announced results from a large real-world multicentre study demonstrating high rates of durable healing in chronic lower extremity wounds using its Topical Wound Oxygen (TWO2) therapy.

The retrospective cohort study, published in the Journal of Vascular Surgery-Vascular Insights, evaluated 3,126 patients with complex wounds, including diabetic foot ulcers, venous leg ulcers and arterial ulcers. Patients had previously failed to heal with advanced wound care for an average of seven months.

AOTI reported that 64.8% of patients achieved complete wound healing within a mean of 4.2 months, while recurrence rates remained low at 2.7% over an average follow-up period of 13.9 months. The therapy also demonstrated reductions in hospitalisations and amputations, with rates of 3.7% and 6.1% respectively in the study population.

The company said the findings reinforce the effectiveness of TWO2 therapy as an adjunct to standard care, supporting improved clinical outcomes in high-risk patients and building on existing clinical trial and real-world evidence.